Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Buys FerroKin BioSciences To Further Hematology Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire gains an iron chelator in Phase II development in exchange for $100 million upfront and post-closing milestones of $225 million.

You may also be interested in...



Start-Up Quarterly Statistics, Q1 2012

Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.

Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated

Distributed free of charge to U.S. patients with Genzyme’s Fabrazyme in short supply, Replagal seemed destined for quick approval, but FDA has signalled otherwise.

Deals of the Week: Stada/Grunenthal, Stada/Spirig, Shire/Sangamo

While 2012 promises to be a lucrative for generic drug companies, they now face their own reverse patent cliff. Some, therefore, are looking to diversify into branded products.

Topics

Related Companies

UsernamePublicRestriction

Register

PS073886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel